Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 12
Submit an article Journal homepage
1,480
Views
13
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review

Min JinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaView further author information
,
Jun CaiDepartment of Oncology, First Affiliated Hospital of Yangtz University, Jingzhou, ChinaView further author information
,
Xuan WangDepartment of Oncology, First Affiliated Hospital of Yangtz University, Jingzhou, ChinaView further author information
,
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCorrespondence[email protected]
View further author information
&
Yingchao ZhaoCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCorrespondence[email protected]
View further author information
Pages 1088-1092 | Received 12 Jan 2018, Accepted 17 Jun 2018, Published online: 15 Aug 2018

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
  • Siporin C. The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities. Annu Rev Microbiol. 1989;43:601–627. doi:10.1146/annurev.mi.43.100189.003125.
  • Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs. 2015;20:331–346. doi:10.1517/14728214.2015.1036739.
  • Matulonis UA. Bevacizumab and its use in epithelial ovarian cancer. Future Oncol. 2011;7:365–379. doi:10.2217/fon.10.167.
  • Du Bois A, Floquet A, Jw K, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374–3382. doi:10.1200/JCO.2014.55.7348.
  • Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075–6081. doi:10.2147/DDDT.S97235.
  • Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. doi:10.1200/JCO.2015.63.5995.
  • Lu W, Jin XL, Yang C, Du P, Jiang F-Q, Ma J-P, Yang J, Xie P, Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther. 2017;18:433–438. doi:10.1080/15384047.2017.1323589.
  • Munroe M, Kolesar J. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Am J Health Syst Pharm. 2016;73:1037–1041. doi:10.2146/ajhp150550.
  • Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F. Niraparib in ovarian cancer: results to date and clinical potential. Ther Adv Med Oncol. 2017;9:579–588. doi:10.1177/1758834017718775.
  • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi:10.3322/caac.20073.
  • Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17:1147–1158. doi:10.1080/14737140.2017.1398088.
  • Lim MC, Randall LM. Role and clinical application of next-generation sequencing (NGS) for ovarian cancer. J Gynecol Oncol. 2017;28:e51. doi:10.3802/jgo.2017.28.e51.
  • Mi YJ, Liang YJ, Huang HB, Zhao H-Y, Wu C-P, Wang F, Tao L-Y, Zhang C-Z, Dai C-L, Tiwari AK, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70:7981–7991. doi:10.1158/0008-5472.CAN-10-0111.
  • Walsh CS. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015;137:343–350. doi:10.1016/j.ygyno.2015.02.017.
  • Kumar D, Kumar S, Gorain M, Tomar D, Patil HS, Radharani NNV, Kumar TVS, Patil TV, Thulasiram HV, Kundu GC. Notch1-MAPK signaling axis regulates CD133(+) cancer stem cell-mediated melanoma growth and angiogenesis. J Invest Dermatol. 2016;136:2462–2474. doi:10.1016/j.jid.2016.07.024.
  • Deng L, Wang Y, Lu W, Liu Q, Wu J, Jin J. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. Onco Targets Ther. 2017;10:1521–1525. doi:10.2147/OTT.S126471.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.